A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)

Clinical trial NCT00963547 · TERMINATED

Trial details

NCT number: NCT00963547
Sponsor: Merck Sharp & Dohme LLC
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumors Breast Cancer

Start date: 2009-09-15
Primary completion: 2011-08-09
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.